Plné znění - 47/2014 Sb. m. s.

Sdělení o přijetí nového znění Přílohy I (Seznam zakázaných látek a metod - Mezinárodní standard) Mezinárodní úmluvy proti dopingu ve sportu

47/2014 Sb. m. s.

Sdělení

INFORMACE

47

XXXXXXX

Xxxxxxxxxxxx xxxxxxxxxxxx xxxx,

xxxxxx xx mění x xxxxxxxx sdělení Xxxxxxxxxxxx xxxxxxxxxxxx xxxx x. 58/2007 Xx. x. x. x x. 46/2008 Xx. x. x. x xxxxxxxxx xxxxxxx Ministerstva zahraničních xxxx x. 98/2013 Xx. m. s. x Xxxxxxxxxxx xxxxxx xxxxx dopingu xx xxxxxx

Xxxxxxxxxxxx xxxxxxxxxxxx xxxx xxxxxxx, xx xxx 11. listopadu 2013 xxxx xxxxxxxxx ředitelkou XXXXXX xxxxxxxx schválení xxxxxx xxxxx Přílohy X - Xxxxxxx xxxxxxxxxx látek x xxxxx - Xxxxxxxxxxx xxxxxxxx Mezinárodní xxxxxx xxxxx xxxxxxx xx xxxxxx.¹⁾

X xxxxx xxxxxx Xxxxxxx X xxxxxxxx xxxxxxx Xxxxxxxxx Xxxxx xxxxxxxxx x prezident xxxxxxxxx xxxxxxxx xxxxxxx x xxxxxxx xxxxx Xxxxxxx I Českou xxxxxxxxxx.

Xxxx xxxxx Xxxxxxx X vstoupilo x xxxxxxxx v xxxxxxx x xxxxxxx 34 xxxx. 3 Úmluvy xxx 1. xxxxx 2014 x xxxxx xxxx xxxxxxxxx v xxxxxxxx x xxx Xxxxxx xxxxxxxxx. Dnem xxxxxx xxxxxx znění Xxxxxxx X v xxxxxxxx xxxxxxxx xxxxxx xxxxx Xxxxxxx X Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx xxxxxx xxxxxx xx 1. xxxxx 2013 x xxxxxxxxx pod č. 98/2013 Sb. m. s.

Xxxxxxxx xxxxx Xxxxxxx I x xxxx xxxxxxx xx xxxxxxx xxxxxx xx vyhlašují současně.

¹⁾ Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx ve xxxxxx xxxxxxx xxx 19. xxxxx 2005 v Xxxxxx xxxx vyhlášena xxx č. 58/2007 Sb. m. s. x č. 46/2008 Sb. m. s.

XXXXXXXXXXX XXXXXX XXXXX XXXXXXX XX XXXXXX
Xxxxxxx X - Xxxxxx xxxxxxxxxx xxxxx x xxxxx - Xxxxxxxxxxx xxxxxxxx
Xxxxx, 1. xxxxx 2014

XXXXXX ZAKÁZANÝCH XXXXX X XXXXX DOPINGU XXX ROK 2014

XXXXXXX XXXXXXXXXXXXX XXXXX

Xxxxxx xx 1. ledna 2014

Xxxxx xxxxxx 4.2.2 Světového xxxxxxxxxxxxxxx xxxxxx xxxxxxx Xxxxxxxx xxxxx xxxxx xxxxxxxxxx xx "Xxxxxxxxxx xxxxx" xxxxx xxxxx xx skupin X1, X2, S4.4, X4.5 x S6(a) x Xxxxxxxxxx metod X1, X2 x M3.

LÁTKY X METODY ZAKÁZANÉ XXXXX (XXX XXXXXXX X XXXX XXXXXX)

XXXXXXXX XXXXX

X0. XXXXXXXXXXX LÁTKY

Jakákoliv xxxxxxxxxxxxx xxxxx, xxxxx xxxx xxxxxxxx x xxxxxxxxxxxxx xxxxxxx Xxxxxxx a xxxx aktuálně schválena xxx humánní xxxxxxxxxxxx xxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxxx xxxxxxxxxx xxxxxx (xxxx. léčiva v xxxxxxxxxxxx xxxx klinickém xxxxxx výzkumu nebo xx xxxxxxxx xxxxxxxxxx, xxxxxxxxxx xxxxx, látky xxxxxxxxx xxxxx xxx xxxxxxxxxxx použití), xx xxxxxxxx stále.

S1. ANABOLICKÉ XXXXX

Xxxxxxxxxx látky xxxx xxxxxxxx.

1. XXXXXXXXXX XXXXXXXXXX XXXXXXXX (AAS):

(a) Xxxxxxxx* XXX, xxxxxxxxxx:

1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3x,17β-xxxx); 1-xxxxxxxxxxxxx (5α-androst-1-en-3,17-dion); xxxxxxxxx (xxxx-4-xx-3β,17β-xxxx); xxxxxxxxxx; xxxxxxxx; xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx); xxxxxxx ([1,2]xxxxxx[4',5':2,3]xxxxxx-4-xx-20-xx-17α-xx); xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx-17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxxxxxxxxxxxxxxxx (17α-xxxxxx-5α-xxxxxxx-2-xx-17β-xx); xxxxxxxxxxx; xxxxxxxxxxxxx (19-xxx-xxxxxx-4-xx-17α-xx); xxxxxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxx (17α-methyl[1,2,5]oxadiazolo[3',4':2,3]-5α-androstan-17β-ol); xxxxxxxxx; 4-hydroxytestosteron (4,17β-dihydroxyandrost-4-en-3-on); xxxxxxxxxx; xxxxxxxxx; mestanolon; xxxxxxxxxx; xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxx; methandriol; metasteron (17β-xxxxxxx-2α,17α-xxxxxxxx-5α-xxxxxxxxx-3-xx); xxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9-xxxx-3-xx); xxxxxx-1-xxxxxxxxxxx (17β-hydroxy-17α-methyl-5α-androst-1-en-3-on); methylnortestosteron (17β-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx); xxxxxxxxxxxxxxxxx; metribolon (xxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9,11-xxxxx-3-xx); xxxxxxxxx; xxxxxxxxx; 19-norandrostendion (estr-4-en-3,17-dion); xxxxxxxxxx; xxxxxxxxxxxxxx; xxxxxxxxxxxx; xxxxxxxx; xxxxxxxxxx; oxymesteron; xxxxxxxxxx; prostanozol (17β-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1'X-xxxxxxxx[3,4,:2,3]-5α-xxxxxxxxxx); xxxxxxxxx; stanozolol; xxxxxxxxx; 1-xxxxxxxxxxx (17β-xxxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxx (17-xxxxxxx-18α-xxxx-19-xxx-17α-xxxxxx-4,9,11-xxxxx-3-xx); trenbolon (17β-xxxxxxxxxx-4,9,11-xxxxx-3-xx) x xxxxx xxxxx x xxxxxxxx chemickou xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx xxxxxx.

(x) Endogenní** XXX, xxxxx xxxx xxxxxx xxxxxxxx:

Xxxxxxxxxxxxx (androst-5-en-3β,17β-diol), xxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx), xxxxxxxxxxxxxxxxxx, xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, XXXX), 3β-xxxxxxxxxxxxx-5-xx-17-xx), xxxxxxxxxxx a xxxxxx xxxxxxxxxx x xxxxxxx, ale ne x omezením xxxxx xx xx:

5α-xxxxxxxxx-3α,17α-xxxx	5-xxxxxxxxxxxxx (androst-5-en-3,17-dion)
5α-androstan-3α,17β-diol	epi-dihydrotestosteron
5α-androstan-3β,17α-diol	epitestosteron
5α-androstan-3β,17β-diol	etiocholanolon
androst-4-en-3α,17α-diol	3α-hydroxy-5αandrostan-17-on
androst-4-en-3α,17β-diol	3β-hydroxy-5αandrostan-17-on
androst-5-en-3β,17α-diol	7α-hydroxy-DHEA
androst-5-en-3α,17α-diol	7β-hydroxy-DHEA
androst-5-en-3α,17β-dioI	7-keto-DHEA
androst-5-en-3β,17α-diol	19-norandrosteron
4-androstendiol (xxxxxxx-4-xx-3β,17β-xxxx)	19-xxxxxxxxxxxxxxxxx

Xxx xxxxx xxxxxxx xxxx xxxxx:

* "exogenní" xx xxxxxxxx x xxxxx, xxxxxx tělo xxxxxxxx xxxxxxxxx xxxxxxxxxxx.

** "xxxxxxxxx " xx xxxxxxxx k xxxxx, xxxxxx xxxx xxxxxxxx xxxxxxxxx produkuje.

2. Ostatní xxxxxxxxxx xxxxx, xxxxxxxxxx:

Xxxxxxxxxxx, xxxxxxxxxx xxxxxxxxxx androgenových xxxxxxxxx (SARM), xxxxxxx, xxxxxxx, xxxxxxxxxx, ale xx s xxxxxxxx xxxxx xx xx.

X2. XXXXXXXXX XXXXXXX, RŮSTOVÉ XXXXXXX X PŘÍBUZNÉ XXXXX

Xxxxxxxxxxx xxxxx a xxxxx látky x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx xxxx zakázány:

1. Xxxxx stimulující erytropoesu (xxxx. xxxxxxxxxxxx (EPO), xxxxxxxxxxx (xXXX), xxxxxxxxxxxxx xxxxxxx vyvolávajícího xxxxxxx (XXX), xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx beta (XXXX), xxxxxxxxxxx /Hematide/);

2. Xxxxxxxxxxxxxxxxxx (CG) a Xxxxxxxxxxxx xxxxxx (LH) x jejich xxxxxxxxxx xxxxxxx u xxxx;

3. Xxxxxxxxxxxxxx x xxxxxx xxxxxxxxxx xxxxxxx;

4. Růstový xxxxxx (XX) x xxxx xxxxxxxxxx xxxxxxx x insulinu xxxxxxx xxxxxxx xxxxxx-1 (XXX-1).

Xxxxx xxxx jsou xxxxxxxx xxxxxxxxxxx xxxxxxx xxxxxxx:

Xxxxxxxxxxxxx xxxxxxx xxxxxxx (XXXx), xxxxxxxxxxxx xxxxxxx xxxxxx (XXX), xxxxxxxxxx růstové xxxxxxx (MGF), xxxxxxx xxxxxx odvozený x xxxxxxxx xxxxxxxx (XXXX) x xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx xxxxxx (VEGF), stejně xxxx xxxxxxxxx xxxx xxxxxxx faktory ovlivňující xxxxxxx xxxx xxxxxxxxx xxxxxxxx svalů, xxxxx x vaziva, krevní xxxxxxxx, xxxxxxx xxxxxxx, xxxxxxxxxxxxx kapacitu xxxx xxxxxxxxxxx xxxx svalových xxxxxx;

x xxxxx xxxxx x podobnou chemickou xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

X3. XXXX2- XXXXXXXX

Xxxxxxx xxxx-2 xxxxxxxx, xxxxxx xxxxx xxxxxxxxxx xxxxxxxxx isomerů (např. x- a x-), xxxx zakázáni xxxxx xxxxxxxxxxx xxxxxxxxxxx (maximálně 1600 xxxxxxxxxx xx 24 xxxxx), inhlalačního xxxxxxxxxxx (maximální xxxxxx xxxxx 54 xxxxxxxxxx xx 24 xxxxx) x xxxxxxxxxxx, xxxxx xxxx podány x xxxxxxxx x xxxxxxx x xxxxxxxxxxx xxxxxxxx xxxxxxx xxxxxxx.

Xxxxxxxxxx xxxxxxxxxxx x moči x xxxxxxxxxxx xxxxx než 1000 xx/xx x xxxxxxxxxx xxxxxxxxxxx x xxxx x xxxxxxxxxxx xxxxx xxx 40 xx/xx xxxxxx xxxxxxxxxx xx zamýšlené terapeutické xxxxxxx, xxx xxxx xxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxx xxxxx, xxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxx, xx xxxxxxxxxx xxxxxxxx byl xxxxxxxx xxxxxxxx xxxxxxxxxxxx xxxxxxxxx dávky xxxxx xxx výše uvedené xxxxxxx.

X4. XXXXXXXXX A XXXXXXXXXXX XXXXXXXXXX

Xxxxxxxx je xxxxxxxxxxx:

1. Inhibitory xxxxxxxx, xxxxxxxxxx:

Xxxxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxx-1,4,6-xxxxx-3-17-xxxx (xxxxxxxxxxxxxxxxx), 4-androsten-3,6,17-trion (6-oxo), xxxxxxxxx, formestan, letrozol, xxxxxxxxxxx, xxx ne x xxxxxxxx xxxxx xx xx.

2. Xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx receptorů (XXXX), xxxxxxxxxx:

Xxxxxxxxx, tamoxifen, xxxxxxxxx, ale xx x xxxxxxxx pouze xx ně.

3. Xxxxxxx xxxxxxxxxxxxxx látky xxxxxxxxxx:

Xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxx, ale xx s xxxxxxxx xxxxx na xx.

4. Xxxxx modifikující xxxxxx xxxxxxxxxx včetně xxxxxxxxxx xxxxxxxxxx, xxx xx x omezením xxxxx xx ně.

5. Xxxxxxxxxxx xxxxxxxxxx:

x) Insuliny;

b) Xxxxxxxx xxxxx xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxxx /Peroxisome Proliferator Xxxxxxxxx Receptor δ (XXXXδ) xxxxxxxx/ (xxxx. XX 1516) x Xxxxxxxx proteinkinasové osy xxxxxxxxxx AMP x xxxxxxxxxxx s XXXX xxxxx /PPARδ-AMP-activated protein xxxxxx (XXXX) axis xxxxxxxx/ (xxxx. XXXXX)

X5. XXXXXXXXX A XXXXXXX XXXXXXXXX LÁTKY

Maskovací látky xxxx zakázané. Xxxxxxxx:

Xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxxxxx (xxxx. xxxxxxxx, xxxxxxxxxx xxxxxx xxxxxxxx, xxxxxxxx, xxxxxxxxxxxxxxxxxx x xxxxxxxxx), probenecid x xxxxx xxxxx x xxxxxxxxx xxxxxxxxxxxx xxxxxx. Lokální podání xxxxxxxxxxxx xxx xxxxx xxxxxxxx není xxxxxxxx.

Xxxxxxxxx xxxxxxxx:

Xxxxxxxxxxxx, amilorid, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxx, xxxxxxxx, xxxxxxxx etakrynová, xxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxx (xxxx. bendroflumethiazid, xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx), xxxxxxxxxx, vaptany (xxxx. xxxxxxxxx) a xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx podobnými biologickými xxxxxx (kromě drospirenonu, xxxxxxxxx x lokálního xxxxxx dorzolamidu x xxxxxxxxxxxx, které nejsou xxxxxxxx).

Xxx použití (Při Xxxxxxx, xxxxxxxx Xxxx Xxxxxx) jakéhokoliv xxxxxxxx xxxxx xx xxxxxxxxxx xxxxxxxx xxxxxxx (xx. xxxxxxxxxx, xxxxxxxxxx, xxxxx, xxxxxxx, xxxxxxxxxxxx x xxxxxxxxxxxxx) xx xxxxxxx x xxxxxxxxxx xxxx xxxxx maskovací látkou xx vyžadováno udělení xxxxxxxxxx Xxxxxxxxxxxx výjimky xx xxxx xxxxx xxxxx x xx, xxxxx již xxxx xxxxxxx xx xxxxxxxxxx xxxx jinou xxxxxxxxx xxxxx.

XXXXXXXX XXXXXX

X1. MANIPULACE X XXXX X XXXXXXXX XXXXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

1. Podání nebo xxxxxxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxx, alogenní (xxxxxxxxx) xxxx heterologní krve xxxx xxxxxxxxx krvinek x jim xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxxx xxxxxxx.

2. Xxxxx xxxxxxxxx spotřeby, xxxxxxx xxxx xxxxxxx xxxxxxx, xxxxxxxxxx modifikované xxxxxxxxxxxxx xxxxxxxx (např. xxxxxx náhražky založené xx xxxxxxxxxxx, xxxxxxxxxxxxxxxxxx xxxxxxxxxxx), xxxxxxxxxxxxxxxxxxx a xxxxxxxxxxx (XXX13), xxx xx s omezením xxxxx na xx. Xxxxxxxxxxxx kyslíkem xxxxxxxx xxxx.

3. Jakákoliv forma xxxxxxxxxxxxxxx xxxxxxxxxx x xxxx nebo s xxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxxxx způsoby.

M2. XXXXXXXX X FYZIKÁLNÍ XXXXXXXXXX

Xxxxxxxx je xxxxxxxxxxx:

1. Xxxxxxxxx, nebo xxxxx x podvod, xx xxxxxx xxxxxxx integritu x xxxxxxxx Vzorků xxxxxxxxxx při Xxxxxxxxx xxxxxxxx. Xx zahrnuje xxxxxx x/xxxx xxxxxx (xxxx. xxxxxxxxxx) xxxx, xxx xx s xxxxxxxx xxxxx na xx.

2. Xxxxxxxxxx xxxxxx x/xxxx injekce xxxx xxx 50 xx xx 6 xxxxx xxxxx infuzí xxxxxxxxx xxxxxxxxx x průběhu xxxxxxxxxxxx xxxxxxx xxxx xxxxxxxxxx vyšetřovacích metod.

M3. XXXXXX XXXXXX

X důvodu xxxxxxxxxx xx xxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxx xxxxxxxxxxx:

1. Xxxxxxxx xxxxxxxx xxxxxxxxxx kyselin xxxx xxxxxx xxxxxxx;

2. Xxxxxxx xxxxxxxxxx nebo xxxxxxxxx modifikovaných xxxxx.

XXXXX X XXXXXX XXXXXXXX XXX XXXXXXX

Xxxxx xxxxxxxxx X0 až S5 x M1 xx X3 uvedených xxxx xxxx Xxx Xxxxxxx xxxxxxxx x xxxxxxxxxxx xxxxxxx:

XXXXXXXX XXXXX

X6. STIMULANCIA

Všechna xxxxxxxxxxx xxxxxx xxxxx xxxxxx xxxxxxxxxx optických xxxxxxx (xxxx. d- x x-) xxxx xxxxxxxx, x xxxxxxxx xxxxxxxx xxxxxxxxx x xxxxxxx jejich xxxxxxxx xxxxxxx a stimulancií xxxxxxxxxx xx Monitorovacího xxxxxxxx pro xxx 2014*.

Xxxxxxxxxxx xxxxxxxx:

(x) Xxxxxxxxxxxx xxxxxxxxxxx:

Xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, amifenazol, xxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxx, fendimetrazin, xxxxxxxxx, fenfluramin, xxxxxxxx, xxxxxxxxxxx, fenproporex, fentermin, xxxxxxxxxxxx /4-fenylpiracetam (xxxxxxxx)/, xxxxxxxxxx, xxxxxxxxxxx, xxxxxx, xxxxxxxxxxx, xxxxxxxxxx, mefenorex, xxxxxxxxxxx, xxxxxxxxxxxx (d-), xxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxx, x-xxxxxxxxxxxxxxx, xxxxxxxxxx, prolintan.

Stimulancium, xxxxx xxxx xxxxxxxx xxxxxxx x xxxxx xxxxxxxx, xx Xxxxxxxxxxx xxxxxx.

(x) Xxxxxxxxxx stimulancia (xxxxxxxx):

Xxxxxxxxx (xxxxxxxxx)****, benzfetamin, xxxxxxxxxxxxxxxxx, xxxxxxx***, xxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxxx, hydroxyamfetamin (parahydroamfetamin), xxxxxxxxxxxx, katin**, xxxxxxx x jeho xxxxxxx (xxxx. mefedron, xxxxxxxxx, xxxx-xxxxxxxxxxxxxxxxxxxxx), xxxxxxxxxxxxxxx, meklofenoxát, xxxxxxxxxxxx***, xxxxxxxxxxxxxxxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxx), xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, oxilofrin (xxxxxxxxxxxxx), xxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxx, pseudoefedrin*****, selegilin, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx), xxxxxxxxxxxx, xxxxxxxxxxxxx x další xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx účinky.

* Xxxxxxxxxxx xxxxx zahrnuté do Xxxxxxxxxxxxxx programu 2014 (xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxx, xxxxxxx, pipradrol, xxxxxxxx) xxxxxx xxxxxxxxxx xx Xxxxxxxx látky.

** Xxxxx xx zakázaný xxxxx při xxxxxxxxxxx xxxxx xxx 5 xxxxxxxxxx x 1 xx xxxx.

*** Xxxxxxx x xxxxxxxxxxxxx xxxx xxxxxxxx xxx xxxxxxxxxxx xxxxx xxx 10 xxxxxxxxxx x 1 xx moči.

**** Xxxxxxx xxxxxx xxxxxxxxxx (xxxxxxxxxx) (xxxx. xxxxx, xxxx xxxxxxxx) xxxx jeho xxxxxx společně x xxxxxxxxx xxxxxxxxxx není xxxxxxxx.

***** Xxxxxxxxxxxxx je xxxxxxx, pokud xxxx xxxxxxxxxxx x moči xx vyšší xxx 150 xxxxxxxxxx xx xxxxxxxx.

X7. XXXXXXXXX

Xxxxxxxx je xxxxxxxxxxx:

Xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxx(xxxxxx), xxxxxxxx x jeho xxxxxxxx, xxxxxxxxxxx, metadon, xxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxx.

X8. XXXXXXXXXXX

Xxxxxxxx (xxxx. xxxxx, konopí x marihuana) xxxx xxxxxxxxxx delta9-tetrahydrokanabinol (XXX) x kanabimimetika (xxxx. "Xxxxx", JWH018, XXX073 x XX-210) xxxx xxxxxxxx.

X9. XXXXXXXXXXXXXXXXXXXX

Xxxxxxx xxxxxxxxxxxxxxxxxxxx xxxxxxxx xxxxxx, rektálně, xxxxxxxxxx xxxx xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxx.

XXXXX XXXXXXXX X URČITÝCH XXXXXXXX

X1. ALKOHOL

Alkohol (xxxxxx) xx xxxxxxxx xxxxx Xxx Xxxxxxx x xxxxxxxxxxxxx xxxxxxxx. Xxxxxxx xx bude provádět xxxxxxxx xxxxxxxx a/nebo xxxxxxxx xxxx. Prahová xxxxxxx pro xxxxxxxx xxxxxxxxxxx xxxxxxxx xx xxxxxxxxxxxx xxxxxxxxxxx alkoholu x xxxx 0.10 x/x.

• Automobilový xxxxx (XXX)

• Karate (XXX)

• Xxxxxxx sporty x xxxxxxxxxxxx (XXX)

• Xxxxxxxxxxx (XX)

• Motocyklový sport (XXX)

• Xxxxx xxxxxxxxxx (XXX)

X2. XXXX-XXXXXXXXX

Xxxxx xxxx xxxxx určeno, beta-blokátory xxxx xxxxxxxx xxxxx Xxx Xxxxxxx x xxxxxxxxxxxxx xxxxxxxx.

• Xxxxxxxxxxxx xxxxx (XXX)

• Xxxxxxxx (xxxxxxx xxxxxxxxxx) (XXXX)

• Xxxx (XXX)

• Xxxxxxxxxxx (XX) (xxxxxxxx xxxx Xxxx xxxxxx)

• Lyžování (XXX) - xxxxx xx xxxxxx a xxxxxxxxxxx lyžování-skoky x X-xxxxx, x snowboard X-xxxxx x "xxx xxx"

• Střelba (ISSF, XXX) (xxxxxxxx xxxx Xxxx xxxxxx)

• Xxxxx (XXX)

Xxxx-xxxxxxxxx zahrnují následující xxxxx:

Xxxxxxxxxx, xxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxxx, bunolol, xxxxxxxxxx, xxxxxxx, karteolol, xxxxxxxxxx, xxxxxxxxx, levobunolol, xxxxxxxxxxxx, metoprolol, xxxxxxx, xxxxxxxxxx, pindolol, xxxxxxxxxxx, xxxxxxx, xxxxxxx, xxx xx s omezením xxxxx na ně.

Xxxxxxxxx

Xxxxxx xxxxxxx x. 47/2014 Xx. m. x. xxxxx účinnosti xxxx 20.9.2014.

Xxxxxx xxxxxxx x. 47/2014 Sb. x. x. xxx xxxxxx xxxxxxx xxxxxxxxx č. 19/2017 Sb. m. s. s účinností xx 6.4.2017.

Xxxxx jednotlivých xxxxxxxx xxxxx xxxxxx xxxxxxxx xxxxxxxx x xxxxxxxx xxxx aktualizováno, xxxxx xx xxxx xxxxxx xxxxxxxxx změna xxxxx xxxxxxxxx xxxxxxxx xxxxxxxx.